anti-CD19 CAR iNKT-cell therapy(Sph Biotherapeutics)

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug Nameanti-CD19 CAR iNKT-cell therapy(Sph Biotherapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > NKT cell therapy > Invariant natural killer T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > NKT cell therapy > Chimeric antigen receptor NKT cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSPH Biotherapeutics (Shanghai) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSPH Biotherapeutics (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A